Public Offering

Metropolitan Bank Holding Corp. priced a public offering of 2.1 million shares at $85.00 per share, aiming to raise approximately $178.5 million. This capital will support organic growth, investments in its banking subsidiary, and working capital. The move strengthens the bank amid financial sector volatility, reflecting investor confidence in its business model and resilience. The funds will likely fuel technology, digital capabilities, and talent expansion, positioning Metropolitan Bank for sustained success.

Twin Vee PowerCats is pricing a public offering of common stock at $0.47 per share, a steep discount to recent trading levels. The offering is expected to raise approximately $3 million for working capital and general corporate purposes. This move, along with historical equity raises, has negatively impacted the company’s stock price, indicating investor concerns about dilution and ongoing reliance on external financing to manage operations amidst profitability challenges.

Galecto has priced a public offering of common stock, aiming to raise approximately $275 million before expenses. The offering includes an option for underwriters to purchase additional shares, potentially increasing total proceeds to around $317 million. This capital infusion will support the biopharmaceutical company’s development of innovative therapies for blood cancers, including its myeloproliferative neoplasm portfolio and acute myeloid leukemia treatments. The offering is expected to close around February 12, 2026.

Curbline Properties Corp. has priced an underwritten public offering of common stock, aiming to raise approximately $204 million in gross proceeds through forward sale agreements. The transaction, managed by Morgan Stanley and BofA Securities, is expected to close on February 12, 2026. The company will physically settle the agreements within approximately 18 months, using net proceeds for general corporate purposes, including acquisitions and working capital. Underwriters have a 30-day option to purchase additional shares.

Dakota Gold Corp. is raising approximately $75 million through a public offering of 12,336,000 common shares, with an option for underwriters to purchase an additional 1,850,400 shares, potentially bringing the total to $86.25 million. Proceeds will fund working capital and general corporate purposes, supporting exploration in South Dakota’s Homestake District. The offering is led by BMO Capital Markets and Scotiabank.

nLIGHT, Inc. has priced a public offering of common stock, raising approximately $175 million before expenses. The funds will support general corporate purposes, including working capital and capital expenditures, enabling the company to advance its high-power laser technologies for critical applications. The offering includes an option for underwriters to purchase additional shares.

CION Investment Corporation has priced a $125 million offering of unsecured notes due 2031. The net proceeds, estimated at $121.25 million, will primarily be used to reduce outstanding borrowings under its senior secured credit facilities. The notes carry a 7.50% annual coupon, payable quarterly, and mature on March 31, 2031. This move aims to enhance financial flexibility and strengthen CION’s credit profile as a business development company investing in middle-market loans.

5E Advanced Materials successfully priced an upsized public offering, raising approximately $36 million to fund its boron and lithium projects. The capital will advance its small-scale boron facility, wellfield development, commercial mine plan, and FEED for operations. This strategic move supports the company’s vertical integration goals and its position in high-growth clean energy and transportation sectors.

Axogen has priced an upsized public offering of common stock, aiming to raise approximately $124 million in gross proceeds. The company intends to use these funds to pay off its term loan facility, bolster working capital, and support future growth initiatives. This move follows recent strong revenue reports and FDA approval for its AVANCE product, positioning Axogen for continued expansion in the peripheral nerve repair market.

Erasca, Inc. has priced an upsized public offering of common stock, securing $225 million in gross proceeds. This capital infusion, at $10.00 per share, will advance the company’s pipeline of therapies for RAS/MAPK pathway-driven cancers. The funds are earmarked for research and development, supporting product candidates, and general corporate purposes, reflecting strong investor confidence.